Literature DB >> 24797576

Interventional cardiology: Outcomes in coronary stent trials--1 year is not enough.

Vasileios F Panoulas1, Antonio Colombo2.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24797576     DOI： 10.1038/nrcardio.2014.63

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  9 in total

1.  Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial.

Authors:  Giulio G Stefanini; Bindu Kalesan; Patrick W Serruys; Dik Heg; Pawel Buszman; Axel Linke; Thomas Ischinger; Volker Klauss; Franz Eberli; William Wijns; Marie-Claude Morice; Carlo Di Mario; Roberto Corti; Diethmar Antoni; Hae Y Sohn; Pedro Eerdmans; Gerrit-Anne van Es; Bernhard Meier; Stephan Windecker; Peter Jüni
Journal:  Lancet       Date:  2011-11-08       Impact factor: 79.321

2.  Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV).

Authors:  Lisette Okkels Jensen; Per Thayssen; Henrik Steen Hansen; Evald Høj Christiansen; Hans Henrik Tilsted; Lars Romer Krusell; Anton Boel Villadsen; Anders Junker; Knud Nørregaard Hansen; Anne Kaltoft; Michael Maeng; Knud Erik Pedersen; Steen Dalby Kristensen; Hans Erik Bøtker; Jan Ravkilde; Richardo Sanchez; Jens Aarøe; Morten Madsen; Henrik Toft Sørensen; Leif Thuesen; Jens Flensted Lassen
Journal:  Circulation       Date:  2012-02-03       Impact factor: 29.690

Review 3.  Lower levels of in-stent late loss are not associated with the risk of stent thrombosis in patients receiving drug-eluting stents.

Authors:  Fernando Rivero; Raúl Moreno; Laura Barreales; Guillermo Galeote; Angel Sánchez-Recalde; Luis Calvo; Santiago Jimenez-Valero; Alexis Villate; Mauricio Vanegas; José-Luis López-Sendón
Journal:  EuroIntervention       Date:  2008-05       Impact factor: 6.534

4.  Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.

Authors:  David E Kandzari; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; Charles O'Shaughnessy; Michael W Ball; Mark Turco; Robert J Applegate; Paul A Gurbel; Mark G Midei; Sejal S Badre; Laura Mauri; Kweli P Thompson; LeRoy A LeNarz; Richard E Kuntz
Journal:  J Am Coll Cardiol       Date:  2006-11-28       Impact factor: 24.094

5.  Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study.

Authors:  Marco Valgimigli; Athanasios Patialiakas; Attila Thury; Salvatore Colangelo; Gianluca Campo; Matteo Tebaldi; Imre Ungi; Stefano Tondi; Marco Roffi; Alberto Menozzi; Nicoletta de Cesare; Roberto Garbo; Emanuele Meliga; Luca Testa; Henrique M Gabriel; Flavio Airoldi; Marco Ferlini; Francesco Liistro; Antonio Dellavalle; Pascal Vranckx; Carlo Briguori
Journal:  Am Heart J       Date:  2013-09-26       Impact factor: 4.749

6.  Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial.

Authors:  Michael Maeng; Hans Henrik Tilsted; Lisette Okkels Jensen; Lars Romer Krusell; Anne Kaltoft; Henning Kelbæk; Anton B Villadsen; Jan Ravkilde; Knud Nørregaard Hansen; Evald Høj Christiansen; Jens Aarøe; Jan Skov Jensen; Steen Dalby Kristensen; Hans Erik Bøtker; Leif Thuesen; Morten Madsen; Per Thayssen; Henrik Toft Sørensen; Jens Flensted Lassen
Journal:  Lancet       Date:  2014-03-14       Impact factor: 79.321

7.  Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).

Authors:  David E Kandzari; Laura Mauri; Jeffrey J Popma; Mark A Turco; Paul A Gurbel; Peter J Fitzgerald; Martin B Leon
Journal:  JACC Cardiovasc Interv       Date:  2011-05       Impact factor: 11.195

8.  Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial.

Authors:  Edoardo Camenzind; William Wijns; Laura Mauri; Volkhard Kurowski; Keyur Parikh; Runlin Gao; Christoph Bode; John P Greenwood; Eric Boersma; Pascal Vranckx; Eugene McFadden; Patrick W Serruys; William W O'Neil; Brenda Jorissen; Frank Van Leeuwen; Ph Gabriel Steg
Journal:  Lancet       Date:  2012-08-27       Impact factor: 79.321

9.  Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III.

Authors:  Akiyoshi Miyazawa; Junya Ako; Yoichiro Hongo; Seung-Ho Hur; Ichizo Tsujino; Brian K Courtney; Ali H M Hassan; David E Kandzari; Yasuhiro Honda; Peter J Fitzgerald
Journal:  Am Heart J       Date:  2007-09-14       Impact factor: 4.749
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.